Final notice from CMS changes the 1.9% pay cut to 0.4% increase, but that's only half the story
Exclusive video of Pfizer's Dave Mouleson the relationship between payers and pharmaceutical manufacturers.
Exclusive video of Edith Rosato, AMCP CEO on the formulary of the future.
In yesterday’s pipeline update, Chris Peterson, PharmD, a director in the Emerging Therapeutics department at Express Scripts, reviewed the trend in FDA approvals and noted several of the key therapeutic areas with recent generics.
More than 2,000 biomarker tests are available, and the NCCN Biomarkers Compendium contains information designed to support decision-making around the use of such testing in patients with cancer
While Medicare will use blunt instruments to institute payment reform, private payers will be more nimble, causing providers to abandon fee-for-service Medicare in favor of Medicare Advantage.
To help manage costs, the panel noted that managed care organizations could move coverage of the new orals into the pharmacy benefit
Increasing costs, loss of drug exclusivity and crowded drug classes have prompted the need for better outcomes data to ensure optimization of payer resources
FDA is slowly implementing draft guidelines for bringing biosimilars to market, while states are enacting laws requiring additional notification and record keeping for the products
More evidence-based treatment sequencing must be put into practice to reduce the number of medications patients use on a trial-and-error basis